A Phase 3 interventional study of GW815SF HFA MDI and salmeterol and fluticasone propionate in Bronchial Asthma, sponsored by GlaxoSmithKline. Completed at 8 sites in Japan. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2010-06-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 29th largest by enrollment, is one of 8 that started in 2007, is one of 6 in phase 3, and was the 21st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →
Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 128 across the 46 interventional studies. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 146th largest by enrollment of the 238 interventional ones that give a count, is one of 20 that started in 2007, is one of 61 in phase 3, and was the 44th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma.
To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in paediatric patients with asthma.
Inclusion criteria:
A pediatric patient already diagnosed as having bronchial asthma who meets all of the following criteria is eligible for the study:
Inclusion Criteria for Entry in Treatment Period 1 A subject will be randomized to one of the two treatment groups only if he/she has completed the run-in period and meets all the following criteria.
Exclusion criteria:
A patient who applies any of the following criteria is not eligible for the study:
Exclusion Criteria for Entry in Treatment Period 1
Enrolment of a subject completing the run-in period into Treatment Period 1 will not be allowed if any of the following applies:
Exclusion Criteria for Entry in Treatment Period 2
Enrolment of a subject completing the into Treatment Period 2 will not be allowed if any of the following applies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
Drug: GW815SF HFA MDI · Drug: salmeterol and fluticasone propionate
SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
Drug: GW815SF HFA MDI · Drug: salmeterol and fluticasone propionate
SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
Drug: GW815SF HFA MDI
Drug pages: Salmeterol Xinafoate · Fluticasone
salmeterol and fluticasone propionate combination
Also known as: salmeterol/fluticasone propionate combination
Drug pages: Salmeterol Xinafoate · Fluticasone
salmeterol + fluticasone propionate
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \[Weeks 1-4/Weeks 7-10\]).
Time frame: Crossover Period Weeks 1-4, and 7-10
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
Time frame: Crossover Period Weeks 1-4, 7-10
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
Time frame: Crossover Period weeks 1-4, 7-10
Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
Time frame: Crossover Period weeks 1-4, 7-10
Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
Time frame: Crossover Period Weeks 1-4, 7-10
Percentage of Subjects With Symptom-Free Nights & Days
Percentage of subjects with Symptom Free Nights \& Days after 4 weeks of Treatment
Time frame: Crossover Period Week 1-4, 7-10
Percentage of Subjects With Rescue Medication-Free Nights and Days
Percentage of subjects with Rescue Medication Free Nights \& Days after 4 weeks of Treatment
Time frame: Crossover Period Weeks 1-4, 7-10
Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).
Time frame: Extension Period Weeks 11-30
Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
Time frame: Extension Period weeks 11-30
Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
Time frame: Extension Period weeks 11-30
Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
Time frame: Extension Period weeks 11-30
Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
Time frame: Extension Period weeks 11-30
Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment
Percentage of subjects with Symptom Free Nights \& Days after 20 weeks of Treatment (at week 30).
Time frame: Extension Period Weeks 11-30
Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment
Percentage of subjects with Rescue Medication Free Nights \& Days after 20 weeks of Treatment (at week 30).
Time frame: Extension Period Weeks 11-30
| Milestone | SFC 50/100 Mcg/Day First | SLM 50 Mcg + FP 100 Mcg/Day First |
|---|---|---|
| Started | 26 | 25 |
| Completed | 26 | 25 |
| Not completed | 0 | 0 |
| Milestone | SFC 50/100 Mcg/Day First | SLM 50 Mcg + FP 100 Mcg/Day First |
|---|---|---|
| Started | 26 | 25 |
| Completed | 25 | 25 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | SFC 50/100 Mcg/Day First | SLM 50 Mcg + FP 100 Mcg/Day First |
|---|---|---|
| Started | 25 | 25 |
| Completed | 25 | 25 |
| Not completed | 0 | 0 |
| Milestone | SFC 50/100 Mcg/Day First | SLM 50 Mcg + FP 100 Mcg/Day First |
|---|---|---|
| Started | 50 | 0 |
| Completed | 50 | 0 |
| Not completed | 0 | 0 |
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \[Weeks 1-4/Weeks 7-10\]).
| Liters/minute | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods | 14.3 ± 4.53 | 17.1 ± 4.53 |
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
| Percentage of predicted value | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods | 5.38 ± 1.543 | 6.73 ± 1.543 |
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
| Percentage of personal best value | SFC 50/100 Mcg/Day | SLM 50mcg + FP 100 Mcg/Day |
|---|---|---|
| Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods | 5.01 ± 1.480 | 6.46 ± 1.480 |
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
| L/min | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods | 16.3 ± 3.74 | 15.8 ± 3.74 |
Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \[Weeks 1-4/Weeks 7-10\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.
| Percentage of circadian variation | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods | 0.06 ± 0.638 | -0.08 ± 0.638 |
Percentage of subjects with Symptom Free Nights \& Days after 4 weeks of Treatment
| Percent of participants | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Baseline | 72.9 | 81.3 |
| After 4 Weeks of Treatment | 91.7 | 81.3 |
Percentage of subjects with Rescue Medication Free Nights \& Days after 4 weeks of Treatment
| Percentage of participants | SFC 50/100 Mcg/Day | SLM 50 Mcg + FP 100 Mcg/Day |
|---|---|---|
| Baseline | 87.5 | 87.5 |
| After 4 Weeks of Treatment | 93.8 | 87.5 |
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).
| L/min | SFC 50/100 Mcg/Day |
|---|---|
| Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period | 3.0 ± 24.56 |
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
| Percentage of predicted value | SFC 50/100 Mcg/Day |
|---|---|
| Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period | 1.46 ± 9.568 |
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
| Percentage of personal best value | SFC 50/100 Mcg/Day |
|---|---|
| Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period | 1.29 ± 8.541 |
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
| L/Min | SFC 50/100 Mcg/Day |
|---|---|
| Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period | 2.7 ± 23.43 |
Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \[Weeks 11-30\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).
| Percentage of circadian variation | SFC 50/100 Mcg/Day |
|---|---|
| Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period | -0.37 ± 3.568 |
Percentage of subjects with Symptom Free Nights \& Days after 20 weeks of Treatment (at week 30).
| Percentage of participants | SFC 50/100 Mcg/Day |
|---|---|
| Baseline | 84.0 |
| After 20 weeks of treatment (at week 30) | 84.8 |
Percentage of subjects with Rescue Medication Free Nights \& Days after 20 weeks of Treatment (at week 30).
| Percentage of participants | SFC 50/100 Mcg/Day |
|---|---|
| Baseline | 90.0 |
| After 20 weeks of treatment (at week 30) | 89.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SFC 50/100 Mcg/Day | — | 0/51 (0%) | 12/51 (23.5%) |
| SLM 50 + FP 100 Mcg/Day | — | 0/50 (0%) | 10/50 (20%) |
| SFC 50/100mcg/Day (Extension Period) | — | 0/51 (0%) | 35/51 (68.6%) |
| Event | SFC 50/100 Mcg/Day | SLM 50 + FP 100 Mcg/Day | SFC 50/100mcg/Day (Extension Period) |
|---|---|---|---|
| Upper Respiratory Tract inflammationRespiratory, thoracic and mediastinal disorders | 7/51 | 3/50 | 17/50 |
| NasopharyngitisInfections and infestations | 2/51 | 4/50 | 7/50 |
| GastroenteritisInfections and infestations | 1/51 | 2/50 | 7/50 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/51 | 1/50 | 5/50 |
| EczemaSkin and subcutaneous tissue disorders | 0/51 | 0/50 | 4/50 |
| StomatitisGastrointestinal disorders | 2/51 | 0/50 | 3/50 |
| Age Continuous(Years) | Overall Study Population |
|---|---|
| Mean | 8.3 ± 2.41 |
| Sex: Female, Male(Participants) | Overall Study Population |
|---|---|
| Female | 17 |
| Male | 34 |
| Race/Ethnicity, Customized(Participants) | Overall Study Population |
|---|---|
| Asian-Japanese Heritage | 51 |
| Region of Enrollment(participants) | Overall Study Population |
|---|---|
| Japan | 51 |
The record gives a start of Apr 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone